– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase (MTP) – – Interim analysis follows […]

(NASDAQ:IMTX), Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months

(Paris:IPN), Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde(R) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer GlobeNewswire May 31, 2025 Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was generally well

You know what they say: April showers bring May's flowers. But they forget to mention that it also brings Todd's once-a-year discount for new clients. To celebrate Todd's anniversary, the generative agriculture firm hosts its biggest offer of the year around this time, and they're happy to announce it's finally here. https://mma.prnewswire.com/media/2700505/logo_Logo.jpg Committed to setting

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer GlobeNewswire May 31, 2025 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for

ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025 GlobeNewswire May 31, 2025 – Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma GlobeNewswire May 31, 2025 Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde(R) regimen in metastatic pancreatic adenocarcinoma GlobeNewswire May 31, 2025 Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median

Maryland Student Wins NFTE Capital Youth Entrepreneurship Challenge Students win $3,000 in Shark Tank-style pitch competition and advance to national finals GlobeNewswire May 31, 2025 Washington, DC, May 31, 2025 (GLOBE NEWSWIRE) — Global entrepreneurship education nonprofit Network for Teaching Entrepreneurship (NFTE) has named four local student businesses as the winners of its annual Capital